S&P Futures
4,139.00 +8.50 (+0.21%) Dow Futures
34,078.00 +83.00 (+0.24%) Nasdaq Futures
12,583.25 +38.00 (+0.30%) Russell 2000 Futures
1,954.30 +4.40 (+0.23%) Crude Oil
78.42 -0.05 (-0.06%) Gold
1,878.40 +1.00 (+0.05%)
Sol-Gel Technologies Ltd. (4SG.F)
- GlobeNewswire
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced today the pricing of a registered direct offering with Armistice Capital for the sale and purchase of 2,560,000 shares of the Company’s ordinary shares, par value NIS 0.1 (the “Ordinary Shares”), a
- GlobeNewswire
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025Conference call to be held this morning at 8:30 a.m. U.S. ET NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPS
- Zacks
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.
